CN111920785B - 异甘草酸或其盐的吸入制剂及其应用 - Google Patents

异甘草酸或其盐的吸入制剂及其应用 Download PDF

Info

Publication number
CN111920785B
CN111920785B CN202010842414.4A CN202010842414A CN111920785B CN 111920785 B CN111920785 B CN 111920785B CN 202010842414 A CN202010842414 A CN 202010842414A CN 111920785 B CN111920785 B CN 111920785B
Authority
CN
China
Prior art keywords
particle size
inhalation
formulation
magnesium isoglycyrrhizinate
magnesium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010842414.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN111920785A (zh
Inventor
顾红梅
王善春
张喜全
徐宏江
宋伟
董平
张颖
陈德洋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN111920785A publication Critical patent/CN111920785A/zh
Application granted granted Critical
Publication of CN111920785B publication Critical patent/CN111920785B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202010842414.4A 2016-04-15 2017-04-14 异甘草酸或其盐的吸入制剂及其应用 Active CN111920785B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201610237175 2016-04-15
CN2016102371753 2016-04-15
CN201780018629.0A CN109069442B (zh) 2016-04-15 2017-04-14 异甘草酸或其盐的吸入制剂及其应用
PCT/CN2017/080583 WO2017177966A1 (zh) 2016-04-15 2017-04-14 异甘草酸或其盐的吸入制剂及其在制备治疗呼吸系统疾病药物中的应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780018629.0A Division CN109069442B (zh) 2016-04-15 2017-04-14 异甘草酸或其盐的吸入制剂及其应用

Publications (2)

Publication Number Publication Date
CN111920785A CN111920785A (zh) 2020-11-13
CN111920785B true CN111920785B (zh) 2022-05-20

Family

ID=60042326

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010842414.4A Active CN111920785B (zh) 2016-04-15 2017-04-14 异甘草酸或其盐的吸入制剂及其应用
CN201780018629.0A Active CN109069442B (zh) 2016-04-15 2017-04-14 异甘草酸或其盐的吸入制剂及其应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780018629.0A Active CN109069442B (zh) 2016-04-15 2017-04-14 异甘草酸或其盐的吸入制剂及其应用

Country Status (13)

Country Link
US (2) US20190117568A1 (https=)
EP (1) EP3443954B1 (https=)
JP (2) JP7166929B2 (https=)
KR (1) KR102410183B1 (https=)
CN (2) CN111920785B (https=)
AU (1) AU2017251548B2 (https=)
BR (1) BR112018071208A2 (https=)
EA (1) EA201892350A1 (https=)
MX (1) MX394106B (https=)
MY (1) MY204600A (https=)
PH (1) PH12018502195A1 (https=)
SG (2) SG11201809042SA (https=)
WO (1) WO2017177966A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119345161A (zh) * 2024-12-25 2025-01-24 江苏长泰药业股份有限公司 一种丙酮酸钠雾化吸入制剂及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101396368A (zh) * 2007-09-29 2009-04-01 江苏正大天晴药业股份有限公司 异甘草酸或其盐在治疗过敏性鼻炎中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891221A (en) * 1988-11-23 1990-01-02 Edward Shanborm Whole blood antiviral process and composition
WO2005004913A1 (ja) * 2003-07-09 2005-01-20 Anges Mg, Inc. デコイを含む薬学的組成物およびその使用方法
EP1643973A1 (en) 2003-07-11 2006-04-12 Glaxo Group Limited Pharmaceutical formulations comprising magnesium stearate
CN101023953B (zh) * 2006-07-24 2010-05-12 南开大学 治疗支气管哮喘的组合物
CN101190232B (zh) * 2006-11-30 2011-08-17 江苏正大天晴药业股份有限公司 一种注射用异甘草酸镁冻干粉针剂及其制备方法
JP2008222682A (ja) * 2007-03-15 2008-09-25 Kumamoto Univ 線維化肺疾患治療薬、気道粘液分泌細胞過形成抑制剤および気道塞栓治療薬
CN101669962A (zh) * 2009-09-18 2010-03-17 杭州市第六人民医院 复合甘草酸氨基酸注射液及其制备方法和应用
WO2012026928A1 (en) * 2010-08-25 2012-03-01 Diacarta Llc Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis
CN103156930A (zh) * 2011-12-19 2013-06-19 张亚军 一种含芍药和甘草提取物的呼吸道给药制剂
UA115544C2 (uk) * 2012-03-13 2017-11-27 Респіверт Лімітед Спосіб підвищення стабільності до хімічного розкладання фармацевтичної композиції та застосування стабілізуючого агента у фармацевтичній коипозиції
CN102920936A (zh) * 2012-09-17 2013-02-13 陈泉生 一种治疗呼吸道疾病的吸盐物及其制作方法
CN104042573A (zh) * 2014-06-03 2014-09-17 青岛市市立医院 一种异甘草酸镁冻干粉针剂及其制备方法
CN106237297A (zh) * 2016-08-30 2016-12-21 吉林紫鑫药业股份有限公司 一种用于治疗慢性支气管炎的药物组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101396368A (zh) * 2007-09-29 2009-04-01 江苏正大天晴药业股份有限公司 异甘草酸或其盐在治疗过敏性鼻炎中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
异甘草酸镁注射液的临床应用;李艳丽，等;《实用药物与临床》;20111231;第14卷(第6期);521-522 *

Also Published As

Publication number Publication date
US11534398B2 (en) 2022-12-27
SG10202010192YA (en) 2020-11-27
AU2017251548B2 (en) 2022-02-17
EA201892350A1 (ru) 2019-06-28
US20190117568A1 (en) 2019-04-25
MY204600A (en) 2024-09-05
CN109069442B (zh) 2020-09-04
JP2021176903A (ja) 2021-11-11
CN109069442A (zh) 2018-12-21
PH12018502195A1 (en) 2019-09-23
SG11201809042SA (en) 2018-11-29
WO2017177966A1 (zh) 2017-10-19
EP3443954B1 (en) 2026-02-25
EP3443954A1 (en) 2019-02-20
AU2017251548A1 (en) 2018-11-15
JP2019511556A (ja) 2019-04-25
MX2018012461A (es) 2019-09-18
US20200368158A1 (en) 2020-11-26
MX394106B (es) 2025-03-24
JP7309791B2 (ja) 2023-07-18
JP7166929B2 (ja) 2022-11-08
BR112018071208A2 (pt) 2019-02-12
KR20180132143A (ko) 2018-12-11
CN111920785A (zh) 2020-11-13
KR102410183B1 (ko) 2022-06-17
EP3443954A4 (en) 2019-11-20

Similar Documents

Publication Publication Date Title
US20090197941A1 (en) Pharmaceutical Compositons for the Treatment of Chronic Obstructive Pulmonary Disease
JP2021102620A (ja) 乾燥粉末配合および使用方法
UA119774C2 (uk) Комбінації формотеролу і будесоніду для лікування хронічної обструктивної хвороби легень (хохл)
CN111920785B (zh) 异甘草酸或其盐的吸入制剂及其应用
Thamby et al. Retrospective studies on drug utilization patterns of asthmatics in a Government hospital in Kedah, Malaysia
CN118526500B (zh) 利匹韦林的医药新用途
JP2021176903A5 (https=)
HK1261173B (en) Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use of the inhaled preparation
HK1261173A1 (en) Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use of the inhaled preparation
JP2019511556A5 (https=)
CN115337311A (zh) 一种治疗呼吸系统疾病的组合物及其制备方法
EA040563B1 (ru) Применение препарата для ингаляции на основе изоглицирризината магния для лечения заболеваний дыхательной системы
WO2021156839A1 (en) Composition in the form of powder containing an extract of cannabis sativa for the treatment of inflammations or infections or allergies of the respiratory system and /or hypersecretion of the mucus, and device for its dosage
CN113599376A (zh) 鸢尾甲黄素a在制备防治支气管哮喘疾病药物中的应用
WO2022166724A1 (zh) 一种福多司坦吸入用溶液制剂及其制备方法和用途
CN119424603B (zh) 复方多黏菌素的吸入制剂及其在制备治疗肺部感染的药物中的应用
CN113491676B (zh) 一种利巴韦林的雾化吸入用溶液及制备方法
Han et al. Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis. Pharmaceutics 2023, 15, 1488
CN119112892A (zh) 伐诺司林二盐酸盐在制备抗慢性阻塞性肺病药物中的应用
CN119258161A (zh) 一种提高呼吸道免疫力的中药组合物及其应用
Pawar et al. Insights of Dry Powder Inhaler: An Emerging Potential Drug Delivery with Novel Therapeutic Carriers
CN117442588A (zh) 一种吸入用人干扰素α2b溶液及其制备方法
JP2022014868A (ja) 慢性閉塞性肺疾患の急性増悪の治療薬の調製におけるＴａｎｒｅｑｉｎｇの応用
HK40030149A (en) Using of tanreqing in the preparation of drugs for the treatment of acute exacerbation of chronic obstructive pulmonary disease
CN114432365A (zh) 一种痰热清雾化吸入制剂及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20230922

Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Patentee after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Patentee after: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd.

Address before: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Patentee before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

TR01 Transfer of patent right